article · Journal of Applied Sciences and Environmental Management
Phosphatidylinositol-3-kinase (PI3K) inhibitors have shown activity in relapsed or refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). PI3K inhibitors have been hampered by poor long-term tolerability and toxicity, which interfere with continuous use. Umbralisib, a dual inhibitor of PI3Kd/casein kinase-1e, exhibits improved selectivity for PI3Kd compared with other PI3K inhibitors. This phase IIb trial was designed to evaluate the efficacy and safety of Umbralisib in patients with R/R iNHL. In this review, Umbralisib achieved meaningful clinical activity in heavily pretreated patients with iNHL. The safety profile was manageable, with a relatively low incidence of immune-mediated toxicities and adverse event-related discontinuations. The theoretical pharmacokinetic behavior comparison between Idelalisib, Duvelisib, and Parsaclisib correlates favorably with the observation in clinical settings.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.48393/imist.prsm/jases-v9i2.66345
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
